BioXcel Therapeutics, Inc. Cash Flow Statement
BTAI|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
BioXcel Therapeutics, Inc. used $58M in operating cash flow and negative free cash flow of $58M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$69.9M | -$179.1M | -$165.8M | -$106.9M |
| Depreciation & Amortization | - | $318.0K | $327.0K | $297.0K |
| Operating Cash Flow | -$57.6M | -$155.0M | -$135.3M | -$82.2M |
| Capital Expenditures | $0 | $20.0K | $139.0K | $445.0K |
| Free Cash Flow | -$57.6M | -$155.0M | -$135.5M | -$82.6M |
| FCF Margin | -8974.3% | -11233.8% | -36128.0% | -22026.1% |